Danish pharmaceutical company Novo Nordisk tackles both obesity and diabetes in their current drug pipeline.
Being overweight or obese has long been known to be a risk factor for type 2 diabetes.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
